Brean Capital analyst Difei Yang was out pounding the table on Zogenix, Inc. (NASDAQ:ZGNX) Wednesday, reiterating a Buy rating and price target of $2.
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that it has …
